| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | K19; CK19; K1CS |
| WB Predicted band size | 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human KRT19 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KRT19抗体的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*"Cytokeratin 19 as a biomarker for circulating tumor cells in solid tumors"*
**作者**：Pantel, K., et al.
**摘要**：该研究探讨了KRT19抗体在检测循环肿瘤细胞(CTC)中的应用，尤其是在乳腺癌和结直肠癌中。研究发现，KRT19作为上皮标志物，可通过免疫荧光或PCR技术高灵敏度检测CTC，但其特异性可能受非肿瘤性上皮细胞干扰。
2. **文献名称**：*"Detection of isolated tumor cells in breast cancer using cytokeratin 19 mRNA and protein markers"*
**作者**：Alix-Panabières, C., et al.
**摘要**：研究比较了KRT19抗体(蛋白水平)与mRNA检测(RT-PCR)在乳腺癌微小转移灶诊断中的效果。结果显示，抗体免疫组化法在淋巴结转移检测中具有临床实用性，但需结合其他标志物以提高准确性。
3. **文献名称**：*"Keratin 19 expression in hepatocellular carcinoma and cholangiocarcinoma: a comparative immunohistochemical study"*
**作者**：Durnez, A., et al.
**摘要**：通过免疫组化分析KRT19在不同肝肿瘤中的表达，发现KRT19抗体可有效区分肝细胞癌(HCC)与胆管癌(CCA)。KRT19在CCA中高表达，而在HCC中通常缺失，提示其作为鉴别诊断工具的潜力。
---
如需更多文献或扩展内容，可进一步指定研究领域(如其他癌症类型或技术方法)。
The keratin 19 (KRT19) antibody is a widely used tool in biomedical research and diagnostics, targeting the KRT19 protein encoded by the *KRT19* gene. KRT19. a member of the type I acidic keratin family, is a 40 kDa intermediate filament protein expressed in simple and glandular epithelial cells, including those in the skin, gastrointestinal tract, and mammary glands. Unlike other keratins, KRT19 lacks a terminal tail domain, contributing to its distinct structural and functional roles in maintaining epithelial cell integrity, mechanical stability, and signaling.
In clinical settings, KRT19 antibodies are pivotal for identifying epithelial-derived tumors, particularly carcinomas. Its expression is a common marker for detecting circulating tumor cells (CTCs) in breast cancer and monitoring metastatic progression. However, KRT19 is absent in certain malignancies (e.g., hepatocellular carcinoma), aiding differential diagnosis. The antibody is also utilized in research to study epithelial-mesenchymal transition (EMT), tissue regeneration, and stem cell biology.
Commercial KRT19 antibodies are typically monoclonal, optimized for techniques like immunohistochemistry (IHC), Western blotting, or immunofluorescence. Challenges include cross-reactivity with other keratins, necessitating rigorous validation. Despite limitations, KRT19 remains a cornerstone biomarker in oncology and epithelial biology, bridging molecular insights with clinical applications.
×
